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ABSTRACT - PURPOSE: MyoNovin is a novel skeletal muscle-regenerating compound developed through 
synthesis of two nitro groups onto a guaifenesin backbone to deliver nitric oxide to skeletal muscle with a potential 
to treat muscle atrophy. The purpose of this study was to utilize in silico, in vitro, and in vivo approaches to 
characterize MyoNovin and examine its safety, biodistribution, and feasibility for drug delivery. METHODS: In 
silico software packages were used to predict the physicochemical and biopharmaceutical properties of 
MyoNovin. In vitro cardiotoxicity was assessed using human cardiomyocytes (RL-14) while effects on CYP3A4 
metabolic enzyme and antioxidant activity were examined using commercial kits. A novel HPLC assay was 
developed to measure MyoNovin concentration in serum, and delineate initial pharmacokinetic and acute toxicity 
after intravenous administration (20 mg/kg) to male Sprague-Dawley rats. RESULTS: MyoNovin showed 
relatively high lipophilicity with a LogP value of 3.49, a 20-fold higher skin permeability (19.89 cm/s*107) 
compared to guaifenesin (0.66 cm/s*107), and ~10-fold higher effective jejunal permeability (2.24 cm/s*104) 
compared to guaifenesin (0.26 cm/s*104). In vitro, MyoNovin was not cytotoxic to cardiomyocytes at 
concentrations below 8 μM and did not inhibit CYP3A4 or show antioxidant activity. In vivo, MyoNovin had a 
short half-life (t1/2) of 0.16 h, and a volume of distribution Vss of 0.62 L/kg. Biomarkers of MyoNovin cardiac and 
renal toxicity did not differ significantly from baseline control levels. CONCLUSIONS: The predicted high 
lipophilicity and skin permeability of MyoNovin render it a potential candidate for transdermal administration 
while its favourable intestinal permeation suggests it may be suitable for oral administration. Pharmacokinetics 
following IV administration of MyoNovin were delineated for the first time in a rat model. Preliminary single 20 
mg/kg dose assessment of MyoNovin suggest no influence on cardiac troponin or β-N-Acetylglucosaminidase .  
 
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For 
Readers”) may comment by clicking on ABSTRACT on the issue’s contents page. 
_______________________________________________________________________ 
 
INTRODUCTION 
 
Skeletal muscle atrophies are characterized by loss 
of skeletal muscle mass due to aging, prolonged 
immobility, denervation, and/or other factors. To our 
knowledge, there is no clinically available 
pharmacological treatment specifically for muscle 
atrophy. Recent work revealed that nitric oxide (NO) 
plays an important role in skeletal muscle 
regeneration. The mechanism of regeneration  
involves the activation of satellite cells that are 
located in close proximity to the skeletal muscle fiber 
and are mitotically quiescent in adult muscle under 
normal physiological conditions. Under some 
conditions, however, such as mechanical stretching 
of muscle fibers and exercise, satellite cells are 
activated, resulting in their proliferation (1, 2). Both 
NO and hepatocyte growth factor are required for 
satellite cell activation (3, 4). NO triggers activation  
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of resting satellite cells to enter the cell cycle (5) and 
hepatocyte growth factor also promotes satellite cell 
cycling by binding to the c-met receptor and 
enhancing cell migration by activated myogenic 
precursor cells (6). The activation of satellite cells, 
thus, contributes to skeletal muscle growth from 
exercise and repair following injury or disease onset 
(7,8). 
A study published by our group showed that 
transdermal administration of a clinically utilized 
nitric oxide donor, isosorbide dinitrate, to normal 
mice promoted satellite cell cycling as it increased 
DNA synthesis by 19-24% in adult muscle (9). 
Similarly, administration of methocarbamol 
produced a 28% increase in DNA synthesis. Co-
administration of isosorbide dinitrate and 
methocarbamol had an additive effect, producing a 
38% increase in DNA synthesis. Such observations 
led to the development of MyoNovin (1-(3,4-bis-
nitrooxy-butoxy)-2-methoxy-benzene) (10), a novel 
nitric oxide donor designed to specifically deliver 
NO to skeletal muscles. MyoNovin was chemically 
synthesized by attaching two nitro groups to 
guaifenesin. Guaifenesin is a mucolytic agent with 
muscle relaxant activity and is an active metabolite 
of methocarbamol. The guaifenesin backbone of 
MyoNovin is anticipated to act as a carrier for 
delivery of NO to skeletal muscle fibers, triggering 
satellite cell activation and ultimately muscle growth 
and repair (9). The same report showed that NO was 
released from homogenates of both liver and skeletal 
muscle after treatment with MyoNovin using 
experiments with electron paramagnetic resonance 
(EPR) spectroscopy. Furthermore, MyoNovin 
increased satellite cell activation and proliferation in 
normal mice as it increased DNA synthesis by 37-
39% 24 h after a single transdermal treatment and 40-
55% following 24 h of a single oral dose (9).  
Given the essential role of NO in muscle 
regeneration, the promising results of MyoNovin 
efficacy both in vitro and in vivo in normal (9) and 
dystrophic mice (11) and the fact that there are no 
viable pharmacological treatments to treat muscle 
atrophy or promote skeletal muscle regeneration, 
MyoNovin could be a feasible therapeutic approach 
to treat conditions such as skeletal muscle injury and 
atrophy of various origins. MyoNovin is a relatively 
new chemical derivative of guaifenesin, and 
synthesis of MyoNovin from guaifenesin would be 
expected to alter the physicochemical and 
biopharmaceutical properties, and pharmacokinetic 
and toxicity profiles of the molecule. Thus, for 
further development of MyoNovin as a potential 
drug to promote muscle growth and repair, it is 
necessary to characterize its safety and explore its 
pharmacokinetics following IV administration. We, 
therefore, conducted the current study to determine 
the feasibility of MyoNovin for drug delivery and 
delineate preliminary pharmacokinetic and selected 
acute toxicity by characterizing the compound in 
silico, in vitro, and in vivo.  
The physicochemical and biopharmaceutical 
properties of MyoNovin were examined for the first 
time utilizing in silico tools, while its effects on 
CYP450 enzymes, antioxidant activity, and cardiac 
safety were examined in vitro. Furthermore, a novel 
reverse-phase high-performance liquid 
chromatography (RP-HPLC) assay was developed to 
measure MyoNovin serum concentrations and to 
delineate its pharmacokinetics in a rat model. The 
cardiac toxicity of MyoNovin was assessed by 
examining its effects on cardiomyocytes in vitro and 
as measured by plasma concentrations of cardiac 
troponin in vivo, while renal toxicity was assessed by 
measuring in vivo levels of a renal toxicity 
biomarker, β-N-acetylglucosaminidase (NAG) and 
urinary output 24 h post-dose.  
 
METHODS 
 
Chemicals and Materials 
Methoxy-phenol (guaiacol), guaifenesin, 
allybromide, silver nitrate, acetone, brine, 
pinostrobin, PEG-400 and DMSO were purchased 
from Sigma (St. Louis, MO, USA). Beta-2-
methoxyphenoxy-lactic acid was obtained from 
BOC Sciences (Shirley, NY, USA). HPLC grade 
acetonitrile and methanol, ethyl acetate, and hexane 
were purchased from Fisher Scientific (Ottawa, ON, 
CA). Ultrapure water from a Milli-Q system 
(Millipore, Billerica, MA, USA) was used for the 
mobile phase. HPLC C18 Phenomenex Kinetex 
column (5 μm, 250 x 4.6 mm), vials, inserts, and, 0.2 
um nylon filter membranes were purchased from 
Phenomenex (Torrance, CA, USA). Sterile 
heparin/50% dextrose catheter lock solution and 
blunt needles were obtained from SAI Infusion 
Technologies, Strategic Applications (Lake Villa, 
IL, USA). Cytochrome P450 kit catalogue # P2857 
was from Life Technologies (Burlington, ON, CA). 
Cayman antioxidant assay kit catalogue # 709001 
was purchased from Cayman Chemical (Ann Arbor, 
MI), cytochrome P450 kit catalogue # P2857 was 
from Life Technologies (Burlington, ON). 
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Chemical Synthesis of MyoNovin 
MyoNovin was synthesized by modifying the Wang 
et al procedure (9). A schematic representation of 
MyoNovin’s synthesis is illustrated in Figure 1. To a 
stirred suspension of methoxy-phenol 1 (1.24 g, 0.01 
mol) in 20 mL of dry acetone, allyl bromide (1.45 g, 
0.012 mol) was added, and the mixture was heated 
overnight at 70 ̊ C. The resulting solution was cooled 
to room temperature and filtered through sintered 
glass funnel to remove any solid residues. The filtrate 
was evaporated under reduced pressure to obtain 2 
allyloxy-2-methoxy-benzene (1.51 g) as a colourless 
liquid. To an ice-cooled stirred solution of compound 
2 (1.0 g; 6.09 mmol) in 12 mL of acetonitrile, silver 
nitrate (0.024 mol) was added followed by iodine 
(1.56 g, 0.024 mol). After iodine has dissolved, the 
reaction was refluxed for 12 h, filtered, poured into 
water and extracted with ethyl acetate. The organic 
layer was washed with brine and evaporated under 
reduced pressure. The oil obtained was purified by 
flash chromatography (eluent from hexanes/EtOAc 
10/1 to 3/1 v/v) to isolate compound 3 (1.24 g) as a 
yellow liquid. The chemical structure of MyoNovin 
was confirmed by H1NMR. H1 NMR (CDCl3): δ = 
3.85 (s, 3H), 4.28 (d, 2H, J= 5.2 Hz), 4.81 (dd, 1H, J 
= 6.6 Hz, J = 12.9 Hz), 4.98 (dd, 1H, J = 3.3 Hz, J = 
12.9 Hz), 5.56-5.64 (m, 1H), 6.87-7.08 (m, 4H). 
 
In Silico Characterization 
Physicochemical and Biopharmaceutical 
Properties  
Gastro-Plus™, Marvin Sketch, and Virtual 
Computational Chemistry Laboratory Computer 
modelling software were utilized to predict the 
physicochemical properties of MyoNovin compared 
to its precursor guaifenesin. Portions of these results 
were generated by GastroPlus software (Version 9.0) 
provided by Simulations Plus, Inc. (Lancaster, 
California, USA).  ADMET Predictor was used for 
modeling the biopharmaceutical and 
physicochemical as well pharmacokinetic 
parameters.  
LogP and LogS values of MyoNovin were 
predicted using online computer software 
(VCCLAB, Virtual Computational Chemistry 
Laboratory) (12,13). pKa, logP, logD at pH 7.4, and 
solubility at pH 7.4 were calculated using 
MarvinSketch™ (ChemAxon Ltd., Cambridge, MA, 
USA), pKa and logP were calculated using 
GastroPlus™ (Simulations Plus, Inc., Lancaster, CA, 
USA).  
 
In vitro Characterization 
Effect of MyoNovin on Metabolic Enzymes 
The effect of MyoNovin on CYP3A4 was examined 
using a CYP Vivid kit from Life Technologies 
following the manufacturer’s instructions. The 
inhibitory effect of MyoNovin on CYP3A4 was 
compared to ketoconazole, a positive inhibitor of 
CYP3A4 and results expressed as % inhibition.  
 
Antioxidant Activity of MyoNovin 
The antioxidant capacity of MyoNovin and 
derivatives was examined at 1, 10, 50, and 100 
μg/mL using a commercial assay kit from Cayman 
Chemical following manufacture’s instructions. The 
assay is based on the ability of the antioxidant in the 
sample to inhibit the oxidation of ABTS (2,2'-azino-
di-[3-ethylbenzthiazoline sulphonate]) to ABTS by 
metmyoglobin. The amount of ABTS produced is 
measured at 750 nm. Presence of antioxidants will 
supress absorbance at 750 nm. Antioxidant activity 
of MyoNovin, guaifenesin, β methoxy-phenoxy-
lactic acid, and allyloxy-2-methoxy-benzene was 
compared to that of Trolox, a water soluble α-
tochopherol analog, and the result was expressed as 
molar equivalents of Trolox. Quercetin was used a 
positive control at 10 and 100 μg/mL. 
 
 
 
 
 
 
 
 
Figure 1. A schematic diagram of MyoNovin synthesis.
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Effects of MyoNovin on Human Cardiomyocytes  
The effect of MyoNovin on cardiac tissue was 
assessed using human cardiomyocytes RL-14 cells 
(American Type Cell Culture Patent Deposit 
Designation PTA-1499 Mannanas, VA, USA). Cells 
were grown in 75 cm2 tissue culture flasks at 37°C in 
a humidified incubator with 5% CO2 containing 
DMEM/F-12, phenol red supplemented with 12.5% 
fetal bovine serum, 20 μM L-glutamate, 100 IU 
penicillin G and 100 μg/mL streptomycin. Following 
3-4 days of incubation, cells were detached using 
trypsin and seeded on 12-well culture plates with 
DMEM/F-12 for 24 h. Cells were subsequently 
washed with PBS, replenished with serum free 
media, and treated with MyoNovin at 2, 4, 8, 16, and 
32 μM for 24 h. Effects of MyoNovin on RL-14 
viability were determined using MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) assay. The assay measures the capacity of 
cells to convert MTT to coloured formazan crystals, 
as described previously (14,15). 
 
HPLC Analysis of MyoNovin 
The Shimadzu HPLC system (Kyoto, Japan) 
consisting of LC-20AB prominence liquid 
chromatograph, SIL-10AF auto-injector, SPD-10AV 
UV-VIS detector, and SCL-10A system controller 
was used for analysis. Separation was achieved using 
a C18 Phenomenex Kinetex column (5 μm, 250 x 4.6 
mm) with UV detection at 275 nm. The mobile phase 
was prepared by mixing acetonitrile:water:methanol 
(75:20:5 v/v), filtered through a 0.2 um nylon filter 
and degassed using reduced pressure prior to use. 
Separation was carried out isocratically at ambient 
temperature (22±1°C) with a flow rate of 0.6 
mL/min. Pinostrobin was used as the internal 
standard. Shimadzu EZStart (Version 7.4) software 
was used for data acquisition and integration. 
Samples were freshly prepared on day of analysis 
and injected into the HPLC system. 
 
Preparation of Standard Solutions 
Stock solutions of MyoNovin (10 mg/mL) and the 
internal standard pinostrobin (1 mg/mL) were 
prepared in DMSO, protected from light, and stored 
at -20 C̊. Working solutions were freshly prepared in 
DMSO to obtain a final concentration of 0.5, 1.0, 
10.0, and 100 μg/mL in rat serum or urine. Standard 
solutions of MyoNovin were prepared by spiking 
MyoNovin (0.5-100 μg/mL) and pinostrobin (10 
μg/mL) in 100 μl of blank rat serum or urine. The 
final concentration of DMSO in spiked standards of 
serum and urine samples did not exceed 3%.  
 
Calibration Curves 
Calibration curves were constructed by plotting the 
peak area ratio of MyoNovin to the internal standard 
(pinostrobin) versus calibration standard 
concentrations of MyoNovin, respectively. 
 
Linearity, Lower Limit of Quantification, and 
Lower Limit of Detection 
Linearity was assessed based on the coefficient of 
determination (r2) of the calibration curve using 
unweighted least squares linear regression. The 
lower limit of quantitation (LOQ) was determined 
based on the lowest concentration that showed a ± 
15% difference between the actual added 
concentration and the average calculated 
concentration. The lower limit of detection (LOD) 
was estimated by comparing signals of known low 
concentrations of MyoNovin spiked in serum to 
blank serum samples without MyoNovin. The 
concentration of MyoNovin with a 1:3 signal to noise 
ratio was considered the lower limit of the analytical 
assay. 
 
Accuracy, Precision and Recovery  
The analytical method was evaluated by calculating 
the intra-day variation of spiked MyoNovin 
standards in rat serum. The intra-day variation was 
determined by comparing 5 replicates of different 
concentrations of MyoNovin (5, 10, 25, 50, and 100 
μg/mL) spiked in serum on 5 days in a 1-week 
period. Calibration curves were established each day. 
Precision was evaluated using Coefficient of 
Variance (CV=SD/Caverage) where SD is the standard 
deviation and Caverage is the mean calculated 
concentration of five replicates. Accuracy was 
assessed by comparing the percentage error of 
calculated concentration to the actual concentration 
added using the equation Bias=(Ccalculated-
Ctheoretical)/Ctheoretical; where Ccalculated is the 
concentration calculated from calibration curve and 
Ctheoretical is the actual concentration added (16).  
Percent recovery was determined by comparing 
peak area ratios of MyoNovin to the internal standard 
(pinostrobin) after extracting MyoNovin from 
serum-spiked samples to respective samples spiked 
in the mobile phase without extraction.  
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In vivo Characterization 
This study was approved by the Bannatyne Campus 
Animal Care Committee at the University of 
Manitoba (protocol #16-004) in conformity with the 
Canadian Council on Animal Care guidelines. Male 
CD® Sprague-Dawley rats (average weight: 250±25 
g) were obtained with the jugular vein surgically 
cannulated using polyurethane-silastic blended 
catheters from Charles River Labs (St. Constant, QC, 
Canada). Rats were housed individually in 
temperature-controlled rooms with a 12 h light/dark 
cycle. All animals had free access to Purina Rat 
Chow (5001) and water, except when specified 
below. Animals were acclimatized in standard cages 
with environmental enrichment for a minimum of 3 
days prior to commencing the pharmacokinetic 
study.   
 
Pharmacokinetic Study 
Jugular cannulas in 5 rats were flushed daily with a 
sterile heparin/50% dextrose catheter lock solution to 
maintain the patency as advised in the technical 
bulletin supplied with the animals from Charles 
River (17). Each animal was placed in a separate 
metabolic cage overnight and fasted overnight (12 h) 
before drug administration (IV; 20 mg MyoNovin/kg 
BW). The dose was selected based on our previous 
study whereby mice received a single oral dose of 80 
mg/kg (9). MyoNovin was freshly reconstituted in 
3% DMSO and 97% PEG-400 prior to dosing. 
Animals received water ad libitum pre- and post-
dosing. Food was provided 2 hours post-dosing. 
Serial blood samples (0.30 mL each) were collected 
at 0, 1, 5, 15, and 30 min, followed by 1, 2, 4, 6, 12, 
and 24 h after IV drug administration. At 24 h 
following drug administration, animals were 
euthanized and exsanguinated. Immediately after all 
blood-collection time points (except the terminal 
point), the cannula was flushed with the same 
volume of 0.9% saline to replenish the collected 
blood volume. The dead volume of the cannula was 
filled with a small volume (~0.15 mL) of heparinized 
lock solution after each blood draw to maintain the 
patency of the cannula. Blood samples were 
collected in polypropylene microcentrifuge tubes 
and centrifuged at 15,000 rpm for 5 min (Beckman 
Microfuge centrifuge, Beckman Coulter Inc., 
Fullerton, CA, USA) to collect serum.  Serum was 
stored at –20 ̊C until sample preparation for HPLC 
drug analysis. Urine samples were also collected 
from metabolic cages at 0, 2, 6, 12, and 24 h 
following MyoNovin administration. The exact urine 
volume of each sample was recorded and urine 
stored at –20 ̊C until preparation for HPLC drug 
analysis. 
 
Treatment of Serum Samples for Analysis 
Pinostrobin (10 μg/mL final concentration) was 
added to 120 μL of all serum samples with the 
exception of the 0 h sample. Samples were vortexed 
for 1 min using a Vortex Genie-2 (VWR Scientific, 
West Chester, PA). One (1.0) mL of cold HPLC 
grade acetonitrile (pre-stored at - 20 ̊C) was added to 
samples to precipitate plasma proteins, vortexed for 
5 min (Vortex Genie-2, VWR Scientific), and 
centrifuged at 15,000 rpm for 15 min before the 
supernatant was transferred to new, labeled 2 mL 
centrifuge tubes. Samples were evaporated to 
dryness using a Savant SPD1010 SpeedVac 
Concentrator without heat (Thermo Fisher Scientific, 
Inc., Asheville, NC). The residue was reconstituted 
with 100 µL of mobile phase, vortexed for 1 min and 
centrifuged at 15,000 rpm for 5 min; the supernatant 
was transferred to HPLC vials and 120 µL was 
injected into the HPLC system.  
 
Pharmacokinetic Analysis 
Pharmacokinetic analysis was performed using data 
from individual rats, and the mean and standard error 
of the mean (SEM) calculated for each group. The 
elimination rate constant (kel) was estimated by 
linear regression of serum concentration in the log-
linear terminal phase. A non-compartmental model 
was fitted to the data for serum concentration versus 
time using Phoenix WinNonlin software Ver. 6.3 
(Pharsight Corporation, Mountain View, CA) to 
calculate the pharmacokinetic parameters in the 
terminal phase, namely mean residence time (MRT), 
total clearance (CLtot), and volume of distribution 
(Vss). The initial maximum serum concentration (C0) 
was calculated by back extrapolation using Phoenix 
WinNonlin software.  
 
Renal Assessment  
Effects on urinary output 
The urinary output of rats over 24 h was monitored 
just before (24 h pre-dose period) and after 
administration of a single IV dose of MyoNovin (20 
mg/kg; 24 h post-dose period). Acute renal toxicity 
induced by any drug may result in a reduced total 
urinary output (18). The total urine volume excreted 
over 24 h post-dosing was compared to the total urine 
volume excreted over the 24 h pre-dosing. 
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β-N-Acetylglucosaminidase (NAG) NAG is a 
lysosomal enzyme found at high concentration in 
kidney tubule cells. Appearance of NAG in the urine 
is used as a sensitive, early marker of renal damage 
(19). Urine samples (100 μl) from pharmacokinetic 
studies after a single IV dose of MyoNovin collected 
at 0, 2, 6, 12, and 24 h were analyzed to determine 
NAG concentrations without dilution on a Medica 
EasyRa automated clinical chemistry analyzer 
(Medica Corporation Bedford, MA) (20). 
Cumulative amounts of NAG excreted in the urine 
over the 24 h post-dosing with MyoNovin were 
compared to cumulative amounts pre-dosing to 
assess renal toxicity.   
 
Assessment of Cardiac Toxicity 
The potential cardiac toxicity of MyoNovin was also 
assessed in vivo utilizing a rat cardiac Troponin-I 
(cTnI) ultra-sensitive ELISA kit assay from Life 
Diagnostics, Inc. (West Chester, PA, USA). Blood 
samples from pharmacokinetic studies were 
collected at 24 h from the jugular vein after a single 
20 mg/kg IV dose (n = 4).  Samples were centrifuged 
to obtain serum and stored at -20° C until analysis. 
On the day of analysis, cTnI concentrations were 
measured in serum samples following 
manufacturer’s instructions.  
 
STATISTICAL ANALYSIS 
 
Compiled data were presented as mean and standard 
error of the mean (mean ± SEM) unless otherwise 
stated. Where possible, data were analyzed for 
statistical significance using SigmaPlot software (v. 
13.0, Systat Software, Inc., San Jose, CA). Student’s 
t-tests were employed for unpaired samples to 
compare means between two groups, while one-way 
ANOVAs were employed to compare the means of 
three or more groups followed by Tukey-Kramer 
multiple comparison Test between groups if 
necessary. A p-value less than 0.05 was considered 
statistically significant. 
 
RESULTS  
 
In silico Characterization 
The physiochemical and biopharmaceutical 
properties of MyoNovin were compared to those of 
its parent compound, guaifenesin. MyoNovin had a 
lower predicted water solubility and higher LogP 
value compared to guaifenesin (Table 1), indicating 
higher lipophilicity. The pH-solubility profile of 
MyoNovin (Figure 2A) shows that the solubility of 
MyoNovin is not affected by changes in pH, while 
the solubility of guaifenesin increased at pH >12 
(Figure 2B). Examination of the solubility of 
MyoNovin in simulated gastric and gastrointestinal 
fluids revealed that MyoNovin has a 1000-fold lower 
predicted solubility in the fasted state in simulated 
gastric fluid (0.004 mg/mL) compared to guaifenesin 
(4.574 mg/mL) (Figure 3). The predicted solubility 
of MyoNovin in simulated intestinal fluid in the fed 
state (0.756 mg/mL) was more than 30-fold higher 
than in the fasted state (0.022 mg/mL), suggesting 
better oral absorption of MyoNovin would be 
achieved when it is administered with food. 
Interestingly, prediction of guaifenesin solubility in 
simulated intestinal fluid showed that its solubility is 
higher in fasted state (2.085 mg/mL) compared to 
that in the fed state (0.272 mg/mL). 
Predicting transmembrane permeability of 
MyoNovin across skin and the intestine using 
ADMET predictorTM software showed that 
MyoNovin is expected to have a 20-fold higher skin 
permeability (19.89 cm/s*107) compared to 
guaifenesin (0.66 cm/s*107) and approximately 10-
fold higher effective jejunal permeability (2.24 
cm/s*104) than guaifenesin (0.26 cm/s*104) (Figure 
4). Moreover, prediction of MyoNovin’s 
permeability across Madin-Darbey Canine Kidney 
(MDCK) cells, epithelial cells of kidney origin and 
commonly used for screening permeability of 
investigational compounds in drug discovery, is 
expected to be (554.691 cm/s*104) 70-fold higher 
than guaifenesin (7.827 cm/s*104). The prediction 
suggests that MyoNovin likely has a useful potential 
to be absorbed through skin and traverse the intestine 
barrier. Additionally, MyoNovin appeared to be 
neither a substrate nor an inhibitor of P-glycoprotein 
(P-gp), a membrane transporter highly expressed in 
intestinal and renal epithelium and responsible for 
efflux of many xenobiotics (e.g., chemotherapeutic 
drugs), as shown in Table 2. 
The predicted effects of MyoNovin on metabolic 
enzymes, calculated using ADMET PredictorTM 
software, showed that MyoNovin is expected to act 
as a substrate of CYP3A4 and as an inhibitor of 
CYP1A2 (Table 2). As well, MyoNovin is expected 
to be ~90% bound to plasma proteins as opposed 
~82% for guaifenesin (Table 3). The predicted 
volume of distribution for MyoNovin was 0.389 
L/kg, which is about 30-fold smaller than that of 
guaifenesin (11.980 L/kg).  
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In vitro Characterization 
Effect of MyoNovin on CYP3A4 
The effect of MyoNovin on CYP3A4 inhibition was 
examined utilizing a commercial assay kit. 
MyoNovin did not inhibit CYP3A4 at concentrations 
between 0.01-50 μM (Figure 5). Only at 100 μM did 
MyoNovin show inhibition of CYP3A4 (30%).  
 
Table 1. Physicochemical properties of MyoNovin and guaifenesin predicted by software packages. 
Compound MyoNovin Guaifenesin 
Structure 
 
 
 
Molecular Weight (g/mol) 288.212 198.218 
Formula C10H12N2O8 C10H14O4 
pKa (MarvinSketch) No ionisable atoms 13.62, 15.56 
pKa (GastroPlus) No ionisable atoms No ionisable atoms 
pKa (GastroPlus, after fitting solubility) No ionisable atoms No ionisable atoms 
logP (MarvinSketch) 2.19 0.34 
logP (neutral, GastroPlus) 3.49 0.59 
logP (VCCLAB) 2.01±0.94 0.67±0.38 
LogP (ADMET Predictor, neural)  3.489 0.494 
logD7.4 (MarvinSketch) 2.187 0.337 
Solubility at pH 7.4 (MarvinSketch) -3.67 logS -1.25 logS 
Solubility at pH 7.4 (MarvinSketch) 0.0616 mg/mL 11.15 mg/mL 
logS (VCCLAB) -2.44 -1.22 
                  
                  
Figure 2. pH-solubility profile of (A) MyoNovin and (B) guaifenesin predicted by Marvin Sketch. 
 
Figure 3. Predicted solubility of MyoNovin and guaifenesin in human simulated gastrointestinal fluids as calculated by 
ADMET Predictor software.
A B 
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Figure 4. Predicted human intestinal and skin permeability of MyoNovin and guaifenesin, and predicted permeability across 
MDCK (canine origin) using ADMET Predictor software.  
 
Table 3. Human pharmacokinetic models of MyoNovin and guaifenesin predicted using ADMET Predictor software. 
Compound MyoNovin Guaifenesin 
Human plasma protein binding (%unbound) 9.994 22.099 
Human volume of distribution (Vd) 0.389 11.980 
Blood-to-plasma concentration ratio (RBP) 0.890 0.869 
Fraction unbound in human liver microsomes (S+fumic) 0.394 0.903 
 
 
 
Figure 5. Percent (%) CYP3A4 enzyme inhibition by MyoNovin (n=4; mean±SEM) expressed as % of the positive inhibitor 
(ketoconazole 10 μM). The concentration of DMSO did not exceed 0.1% in each well. *P<0.05 compared to ketoconazole
Table 2.  Biopharmaceutical properties of MyoNovin and guaifenesin predicted by ADMET Predictor software.  
Compound MyoNovin Guaifenesin 
Diffusion coefficient (cm2/s*105)  0.856 0.569 
P-gp Substrate (likelihood of intestinal efflux by P-gp) No (95%) Yes (91%) 
P-gp Inhibition (intestinal) No (94%) No (72%) 
OATP1B1 Inhibition (hepatic)  No (97%)  No (87%) 
CYP3A4 Inhibition  No No+ 
CYP3A4 Substrate   Yes No+ 
CYP1A2 Inhibition  Yes (96%) Yes (60%)+ 
CYP1A2 Substrate  No (83%) NA 
CYP2D6 Inhibition  No (95%) No+ 
CYP2D6 Substrate No (96%) No (85%)+ 
 +www.Drugbank.ca (21), NA=not available   
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Antioxidant Activity 
Nitric oxide exhibits anti-oxidant activity (22) by 
acting as a scavenger of reactive oxygen species. 
Thus, the antioxidant capacity of MyoNovin was 
examined in vitro. The result in Figure 6 shows that 
there is no difference in the antioxidant activity of 
MyoNovin or its derivatives at 1, 10, 50, and 100 
μg/mL compared to baseline, suggesting that 
MyoNovin and derivatives do not exhibit antioxidant 
activity using this assay. However, a significant 
difference in the antioxidant activity was observed 
between MyoNovin and its derivatives compared to 
quercetin, which is a potent antioxidant.  
 
Effects on Human Cardiomyocytes (RL-14) 
The effects of MyoNovin on human cardiomyocytes 
was investigated after treatment (from 2-32 μM) for 
24 h by the MTT assay. Figure 7 shows that the 
viability of RL-14 cells at 4 μM MyoNovin was 
~94%; since this was not statistically different from 
the untreated control cells, the finding indicated that 
MyoNovin is likely non-toxic to cardiomyocytes at 
concentrations up to 4 μM. At 8 μM cell viability was 
only about 78%, significantly lower than controls, 
suggesting that MyoNovin did induce some 
cardiotoxicity resulting in ~22 % cell death. 
 
HPLC Analysis of MyoNovin (Analytical method 
development and validation) 
A RP-HPLC assay was developed to quantitate 
MyoNovin in serum and urine samples collected 
during pharmacokinetics experiments. Optimal 
separation between MyoNovin and the internal 
standard, pinostrobin, was achieved using the 
chromatography conditions described in methods. 
Chromatograms were free from peaks that co-eluted 
with the peaks of interest. Retention times of 
MyoNovin and pinostrobin were 6.2 and 7.5 min, 
respectively (Figure 8). The acceptance criteria for 
the analytical method were in accordance with Food 
and Drug Administration (FDA) guidelines 23).  
 
Linearity, LOQ, and LOD  
Calibration curves of MyoNovin showed excellent 
linearity and a coefficient of determination (r2) of 
0.99 over the range of 0.5-100 μg/mL. The LOQ was 
5 μg/mL with corresponding CV of 13.21% and bias 
of -10.75% (Table 4). The LOD was determined to 
be 1 μg/mL, based on a 1:3 signal-to-noise ratio.  
 
Accuracy, Precision and Recovery 
The intra-day precision from five runs during one 
week showed that the assay CV% was <15% at the 
lowest concentration and <2% at the highest 
concentration (Table 4). The percent bias was -
10.75% (CV=13.21%) and -2.63 (CV=1.22%) at 5 
and 100 μg/mL, respectively. Percent recovery was 
105% at the lower limit of quantification and 97% at 
100 μg/mL MyoNovin. The results show that intra-
day coefficient of variance and bias intra-day 
variation were both below 15% at 5 μg/mL and 
within ± 5% over the range of 10-100 μg/mL while 
the percent recovery was >97%. These parameters 
indicated that the analytical method was sensitive, 
accurate and reproducible. 
 
 
Figure 6. Antioxidant activity of MyoNovin and its derivatives (n=4±SEM). *P<0.05 compared to quercetin. 
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Figure 7. Viability of human RL-14 cardiac myocytes measured by an MTT assay after treatment with MyoNovin at 
concentrations 2,4,8,16, and 32 μM (0.6,1.2,2.3,4.6, and 9.2 μg/mL, respectively) for 24 hours (n=4; mean ± SEM) relative 
to untreated control. *P<0.05 compared to control. 
 
 
 
Figure 8. Representative chromatograms of (A) blank serum (B) MyoNovin (100 μg/mL) and pinostrobin (10 μg/mL) spiked 
in serum (C) MyoNovin, pinostrobin and M1 1 min after administration of MyoNovin (20 mg/kg) to animals. 
 
 
Table 4. Accuracy and precision of MyoNovin in serum (n=5 days, mean ± SEM) 
Concentration 
 (Added) 
Average  
(Calculated) 
CV (%) Bias (%) Recovery (%) 
5 4.46 ± 0.26 13.21 -10.75 105.16 ± 5.8 
10  10.56 ± 0.21 4.43 5.61 105.13 ± 2.92 
25 27.87 ± 0.39 3.1 11.47 99.34 ± 4.69 
50 53.33 ± 0.95 3.99 6.66 98.34 ± 1.62 
100 97.36 ± 0.53 1.22 -2.63 96.9 ± 4.12 
 
 
A B C 
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In vivo Characterization 
Disposition and Pharmacokinetics of MyoNovin 
after IV Administration 
Following IV administration, MyoNovin was 
detected in serum up to 30 min post-dosing (Figure 
8) with a maximum extrapolated serum 
concentration (C0) of 43.6 ± 8.8 μg/mL. The serum 
disposition profile of MyoNovin showed an initial 
sharp decline in concentration over the first 5 min, 
representing a distribution phase; this was followed 
by a further rapid decline over the next 15-30 min 
(last measurable concentration), representing an 
elimination phase (Figure 9). The serum 
concentration versus time profile followed a bi-
expotential pattern indicating that MyoNovin resides 
beyond the vasculature and penetrates into tissues. 
Interestingly, at 1 min post-dosing, a new peak (M1) 
was also observed at an earlier retention time than 
that of MyoNovin and was detectable for up to 1 h. 
The M1 peak decreased over time, similar to that of 
MyoNovin, indicating that it could be a metabolite of 
MyoNovin formed as result of NO release in vivo. 
Figure 10 shows a proposed schematic for the 
mechanism of NO and M1 release. Figure 11 
illustrates possible metabolic pathways for 
MyoNovin after the release of nitric oxide.  
Table 5 demonstrates the pharmacokinetic 
parameters of MyoNovin following a single IV 
administration (20 mg/kg). The half-life of 
MyoNovin was 0.16 h (Table 5), suggesting that 
MyoNovin remained intact for a short time before 
rapidly undergoing metabolism, possibly after, 
releasing nitric oxide. The volume of distribution Vss 
of MyoNovin was 0.62 ± 61.58 L/kg suggesting that 
it was distributed to tissues in a manner comparable 
to that predicted by ADMET Predictor software 
(Table 3). The total clearance was 8.49 ± 3.35 L/h/kg 
and AUCinf and total body exposure was 8.13 ± 5.23 
μg*h/mL.  
 
Renal Effects 
Effects on urinary output 
Urinary output of rats over 24 h was monitored and 
compared before and after administration of a single 
IV dose of MyoNovin (20 mg/kg). There was no 
significant difference in total urine volume excreted 
pre-dose (24.2±5.9 mL) vs post dose 21.5 ±5.1 mL.   
 
 
 
 
 
Figure 9. A graph of the serum concentration versus time for MyoNovin after IV administration (20 mg/kg, n = 5, mean 
± SEM). The figure insert shows the y-axis of the same serum concentration versus time curve on a Log scale.  
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Table 5. The pharmacokinetics of MyoNovin in rat serum after IV administration (20 mg/kg) (mean ± SEM, n= 5 
unless otherwise stated). 
Pharmacokinetic parameter MyoNovin 
C0 (μg/mL) 43.6 ± 8.82   
Kel (1/h) 12.6 ± 4.73   
t1/2 (h) 0.16 ± 0.1 
AUClast (μg.h/mL) 5.1 ± 2.34 
AUCinf  (μg.h/mL) 8.13 ± 5.23 
Tlast (h)1 0.25  
Vss (L/kg) 0.62 ± 61.58   
CLtotal (L/h/kg) 8.49 ± 3.35  
 
1 Median 
 
 
 
 
Figure 10. Proposed schematic representing MyoNovin biotransformation in vivo, based on reference (24). 
 
 
β-N-Acetylglucosaminidase (NAG) 
Nitric oxide plays important physiological and 
pathophysiological roles in kidney function (30), and 
excessive NO production could induce renal toxicity 
(31). In addition, MyoNovin could be metabolized to 
beta-(2-methoxyphenoxy)-lactic acid, a compound 
that has been localized in the presence of kidney 
stones (32). Therefore, the potential renal toxicity of 
MyoNovin was assessed by measuring β-N-
acetylglucosaminidase (NAG), a sensitive marker of 
kidney injury (33). Cumulative NAG excreted in 
urine 24 h post MyoNovin IV dosing (20mg/kg) was 
not statistically different from the baseline control 
level of cumulative NAG excretion. A positive-
control group of rats received a single IV dose of 
doxorubicin (10mg/kg), a known nephrotoxic anti-
cancer drug where there was a significant increase in 
cumulative urinary NAG excreted over the same 
period of time compared to baseline controls (0.4 
±0.17 vs 0.09±0.1). 
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Figure 11. Schematic representation of proposed metabolic pathways for guaifenesin, based on references (25-29).  
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Effect on Serum Cardiac Troponin 
Nitric oxide can play protective and/or detrimental 
roles in cardiac function (34). The potential cardiac 
toxicity of MyoNovin was assessed by measuring 
levels of cardiac troponin (cTnI), a sensitive marker 
of myocardial damage (35). Cardiac Tn1 
concentrations in serum samples collected 24 h after 
MyoNovin IV administration were not significantly 
different from baseline controls. Figure 12 shows 
cTn1 concentration 24 h post MyoNovin (20mg/kg 
IV) compared to those 24 h following a single IV 
dose of doxorubicin. Although the concentration of 
cTn1 was much higher in the doxorubicin group, it 
was not significantly different in from the control 
concentration, largely due to within-group 
variability.  
 
DISCUSSION 
 
MyoNovin was designed to deliver nitric oxide to 
skeletal muscle, thus providing a novel drug-delivery 
approach by utilizing guaifenesin as a carrier for 
transporting NO (9). While there are no clinically 
viable drugs that directly initiate skeletal muscle 
growth and regeneration, such treatment would be 
beneficial in restoring muscle mass in atrophic and 
some disease conditions. Thus, pharmaceutical 
development of MyoNovin could lead to a viable 
pharmacological approach for the treatment of 
skeletal muscle atrophy associated with aging, disuse 
and denervation, and for the repair of skeletal muscle 
after injury or disease. MyoNovin is a novel drug 
targeted toward skeletal muscle regeneration and 
with potentially lower levels of systemic toxicities 
typically associated with conventional NO donors. 
As MyoNovin is an investigational compound, its 
physicochemical properties, biodistribution, 
pharmacokinetics, and safety have not yet been 
examined. In this report, we characterized 
MyoNovin in silico using computer software to 
explore the physiochemical and biopharmaceutical 
properties. We also developed and validated an 
HPLC assay to quantitate MyoNovin concentrations 
in serum following IV administration, which allowed 
us to elucidate initial pharmacokinetic profile.  
In silico characterization of MyoNovin revealed 
that it has low predicted water solubility, a log P of 
~3.5, reasonable solubility in fed-state 
gastrointestinal fluids, good intestinal permeability, 
and a low likelihood of efflux by transporters (Tables 
1 and 2). These parameters suggest that MyoNovin 
is a potential candidate for oral administration. The 
fact that the solubility of MyoNovin in fed-state 
simulated gastrointestinal fluids is more than 30-fold 
higher than in fasted-state fluids suggests that better 
oral absorption would be achieved when 
administered with food. Given that MyoNovin is a 
neutral compound and that its solubility is generally 
expected to be unaffected by fluctuations in the pH 
according to predictions by GastroPlusTM software 
(Figure 2A), it is possible that MyoNovin solubility 
would be compromised in gastric fluids, as predicted 
by ADMET PredictorTM software (Table 2). Further 
development of an oral formulation, use of an enteric 
coated solid-dosage form of MyoNovin or 
incorporation of an acid-neutralizing excipient into 
the formulation may be useful to overcome the 
limited solubility of the compound in gastric fluids. 
Moreover, if MyoNovin is to be administered as a 
liquid oral formulation, the vehicle used in that 
formulation may affect MyoNovin solubility in 
gastrointestinal fluid and also its absorption from the 
gastrointestinal tract. In previous studies published 
by our group, MyoNovin was administered as a 
liquid formulation in corn oil by oral gavage to mice 
at a dose of 80 mg/kg (9) or as a suspension in canola 
oil (11). Corn and canola oils may have improved the 
solubility of the lipophilic molecule, MyoNovin, and 
also may its absorption from the intestine and 
lymphatics. Most importantly, the oral 
administration of MyoNovin did result in the desired 
pharmacological effect in vivo, as evidenced by the 
increase in DNA synthesis in skeletal muscle 24 h 
post-dose (9).  
Another potential route for MyoNovin 
administration could be transdermal. An ointment 
transdermal formulation of MyoNovin may be 
superior to an oral formulation, due to the ease of 
transdermal application especially in older 
individuals with swallowing difficulties. A potential 
therapeutic barrier to transdermal drug delivery is the 
ability of a drug to permeate across the stratum 
corneum layer of the skin. Prediction of MyoNovin’s 
skin permeability by ADMET predictorTM software 
(19.89 cm/s*107) and its high lipophilicity (predicted 
by GastroPlusTM log P~3.5) renders it a potential 
candidate for transdermal application. Furthermore, 
the vehicle and excipients used in a transdermal 
ointment formulation can also have an effect on the 
permeability of MyoNovin through the skin. 
Administration of MyoNovin as a 2% ointment 
formulation in Dermabase on the shaved skin on the 
back of mice did increase DNA synthesis of
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Figure 12. cTnI concentration (mean ± SEM) after IV administration of MyoNovin (20 mg/kg) and doxorubicin (10 mg/kg) 
compared to control cTnI. Control (n=7), MyoNovin (n=4), and doxorubicin (n=3). There was no statistical difference 
observed among group. 
 
 
skeletal muscles 24 h following application (9), 
demonstrating the feasibility of transdermal 
administration, although it is possible that 
Dermabase itself, may have improved the 
permeation of MyoNovin through the skin. 
The effects of MyoNovin on metabolic enzymes 
were examined in vitro using a commercial assay kit. 
CYP3A4 is the major metabolic enzyme involved in 
first-pass metabolism. Results demonstrated that 
MyoNovin does not inhibit CYP3A4. This 
observation is also consistent with the in silico 
observations as predicted by ADMET PredictorTM 
software (Table 2). Interestingly, the same software 
program also predicted that MyoNovin is a substrate 
of CYP3A4. The high likelihood of MyoNovin as a 
substrate of CYP3A4 suggests that it would likely be 
susceptible to first-pass metabolism, which may 
decrease its oral bioavailability and require a higher 
oral dose for treatment efficacy.    
To examine the disposition of MyoNovin in 
biological fluids and characterize its 
pharmacokinetics, an HPLC assay was developed 
and successfully applied to quantitate the 
concentration of MyoNovin in rat serum after IV 
administration. The IV route was chosen for this 
initial pharmacokinetic study because its 
pharmacokinetic parameters would not be 
contaminated by an absorption phase and/or first-
pass metabolism that affects the outcome of drug 
treatment administered orally. Only male rats were 
used to minimize factors that may contribute to sex-
based differences in metabolism and 
pharmacokinetics (36,37). Male and female rats 
could metabolize MyoNovin to different extents due 
sex dependent hepatic metabolism. Non-metabolic 
sex based differences in clearance and volume of 
distribution are also present in animal species (38, 
39) and may affect the disposition of MyoNovin.  
Moreover, female rats may have higher fat content 
(especially subcutaneous fat) due to estrogen levels 
(40,41) and this may affect the distribution of 
lipophilic drugs. Sex based differences in 
pharmacokinetics may affect serum drug levels and 
thus the minimum toxic dose that could increase 
cardiac and renal toxicity biomarkers may be 
different between male and female rats in our study. 
In this study, MyoNovin was detected in rat 
serum up to 30 min post-dose, with a biexponential 
disappearance from plasma. The terminal half-life 
was very fast, with a t1/2 of 0.16 h. The short half-life 
of MyoNovin may be anticipated since the 
compound is designed to release NO in vivo, leading 
to the formation of a new metabolite. The observed 
half-life of MyoNovin is close to the reported half-
life of its precursor guaifenesin: 0.82 h in rats (42) 
and 1.41 h in ponies (43) after IV administration, and 
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0.6 -1.03 h in humans after oral administration 44).  
Furthermore, detection of MyoNovin in serum for up 
to 30 min post-dosing as well an M1 peak suggested 
that MyoNovin stays intact in the systemic 
vasculature, releasing NO and distributing it to 
tissues before it undergoes biotransformation.  
The reported physiological parameters of a 0.25 
kg rat indicate that the total blood volume is 
approximately 13.5 mL and total body water is 167 
mL (45), which translates to 0.054 L/kg and 0.668 
L/kg, respectively. The observed Vss of MyoNovin 
(0.620 ± 61.58 L/kg) is larger than the total blood 
volume and is almost equal to the total body water; 
these findings suggest that MyoNovin is rapidly 
distributed beyond the systemic circulation. The fact 
that MyoNovin is lipophilic (predicted Log P 3.49, 
Table 1) and Vss is not greater than total water 
volume suggests that MyoNovin may be distributed 
to tissues such as skeletal muscles. Also, the 
observed Vss of MyoNovin is comparable to the 
reported Vss values of guaifenesin, 0.79 L/kg in rats 
(42), 0.79 L/kg in horses (43), and 0.68 L/kg in 
donkeys (43).   
The safety of MyoNovin on cardiac muscles was 
examined both in vitro and in vivo. Human 
cardiomyocytes were cultured in vitro to assess the 
safety of MyoNovin on heart muscle. RL-14 cells are 
a commercially available cell line isolated from 
human ventricular tissue, and are commonly used to 
investigate toxic effects induced by xenobiotics. 
Although there were no in vivo effects of MyoNovin 
on cardiac size noted after 18 days of treatment in 
dystrophic mice (11), the effects of MyoNovin on 
cardiac tissue are not known in any detail. Here, 
cardiomyocytes were treated with MyoNovin at 
several concentrations, 2, 4, 8, 16, and 32 μM to 
assess safety in vitro. Results demonstrated that 
MyoNovin did not induce significant cytotoxicity at 
4 μM or lower as the percent viability was about 94 
% (Figure 7). However, cardiomyocytes treated with 
MyoNovin at 8 μM showed only 77% cell viability, 
suggesting that MyoNovin may be cardiotoxic at 
concentrations at or above 8 μM. In this study, rats 
dosed with 20 mg/kg MyoNovin showed a maximum 
circulating concentration of 43.6 μg/mL (151.3 μM). 
Assuming linear kinetics a dose of 1 mg/kg would 
provide a maximum circulating serum concentration 
of ~8 μM (2.3 μg/mL), which demonstrated cardiac 
toxicity in vitro.  Despite the observed cardiotoxic 
effects of MyoNovin in vitro at 8 μM during the 24 
h of incubation, examination of cardiac troponin 
concentration 24 h after a single IV dose of 
MyoNovin (20mg/kg) in rats showed no acute 
evidence of cardiotoxicity in vivo (Figure 13).  
Furthermore, studies of urinary output and NAG 24 
h after administration of the same dose of MyoNovin 
in vivo showed no initial evidence of renal toxicity 
(Figure 12). Findings therefore suggest that a single 
IV 20 mg/kg dose did not induce acute cardiac or 
renal toxicity up to 24 h post-dosing, despite 
reaching a maximum circulating concentration of 
43.6 ± 8.82 μg/mL (151.3 μM). It is imperative to 
note that our in vivo results are generated only after 
single doses. Further research is needed to ascertain 
the effect of MyoNovin on cardiac cells. 
 
CONCLUSIONS 
 
MyoNovin is a novel synthetic skeletal muscle 
regenerating agent that was developed using 
guaifenesin as a carrier system to deliver NO to 
muscle. Given that there are no viable 
pharmacological treatments for skeletal muscle 
atrophy, MyoNovin and analogues we have 
synthesized could be a feasible therapeutic approach 
to restore loss of skeletal muscle mass associated 
with aging, or to treat diseases by promoting normal 
repair after injury. Use of guaifenesin’s molecular 
skeleton in MyoNovin was intended to enhance the 
localization of NO to skeletal muscle, and thus lower 
its tendency to induce undesirable systemic effects 
associated with conventional NO donors.  
Our preliminary in silico and in vitro 
observations of MyoNovin in this study, along with 
in vivo results from our previous reports (9, 11) 
suggest that intravenous, oral, and transdermal routes 
might all be feasible for MyoNovin administration. 
Pharmacokinetic characterization shows that 
MyoNovin has a short plasma half-life. Previous and 
current results now provide a basis for further 
experiments to explore dosing regimen required to 
achieve optimal therapeutic outcome and delineate 
the toxicokinetic profile of MyoNovin. In addition, 
efforts to study skin flux and optimize MyoNovin 
formulations (particularly solubility) are also 
warranted and are in progress in our laboratory. 
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